VEGFA and non-small cell lung carcinoma: Very intriguingly, our results demonstrated that Endostar plus NP prolonged the DFS of VEGF positive patients with complete resectable NSCLC at stage IIIA to average of 8.27 months with statistical significance when compared to VEGF negative patients (p = 0.037).